A Leading Global Molecular Diagnostic Platform

A best-in-class global molecular diagnostic platform contributing to the prevention of infectious disease transmission and better health for the citizens of the world.

Our Mission

  • Contribute to the early detection and prevention of infectious disease transmission

  • Leverage our proprietary Antisense molecular RNA diagnostic platform across multiple diseases

  • Create highly accurate, quick, affordable, easy to administer and minimally invasive disease diagnostic testing kits

LEARN MORE

Our PRODUCTS

  • The Company’s first product is an Antisense molecular Point Of Care (“POC”) diagnostic test kit that accurately, quickly and affordably detects Covid-19 in less than 5 minutes.

  • Our Antisense molecular POC diagnostic test delivers the gold standard Covid-19 testing accuracy of a RT-PCR test, with the speed of the fastest rapid tests.

  • The Antisense molecular diagnostic platform will be further expanded for use in testing for other diseases.

LEARN MORE

COVID-19

  • 1 billion Covid-19 molecular tests administered globally in 2020

  • Click here for link to Health Canada Covid-19 Infobase

  • Click here for link to US Government CDC Covid-19 Tracker Data

  • Click here for link to University of Oxford – Our World in Data Global Database

RNA Disease Diagnostics Announces University of Maryland School of Medicine Laboratory Secures FDA Registration and Approval as Development Site for Antisense COVID-19 Test

June 3, 2021

BALTIMORE, June 3, 2021 - RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today that the U.S. Food and Drug Administration (FDA) has registered the laboratory of Dipanjan Pan, MSc, PhD at the University of Maryland School of Medicine (UMSOM), as an approved laboratory development site for RNADD's Antisense COVID-19 molecular diagnostic test.

Read More

RNA Disease Diagnostics Further Strengthens Executive Leadership with Appointment of John W. Erickson, Jr. as President

June 1, 2021

RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today the appointment of John W. Erickson, Jr. to the newly created position of President. Mr. Erickson will lead day-to-day operations, reporting directly to RNADD’s co-founder and Executive Chairman, Allan Oberman.

Read More

Exclusive Global License

Investors

We have established a world class executive leadership team, Board of Directors and Board of Advisors, with experience in healthcare, life sciences, medical devices, diagnostics, biotechnology, nanomedicine, drug delivery, and pharmaceuticals. Our financial advisors have decades of global experience in investment banking in the private and public sector.

LEARN MORE